Related Experiment Video
Updated: Jul 6, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Targeting Eg5 using Arry520 combats gastric cancer by inducing monopolar spindles
Na He1, Xinyuan Wei2, Ruofei Sun3
1Department of Oncology, Lanzhou University Second Hospital, Lanzhou, Gansu, China; The Second Clinical Medical College, Lanzhou University, Gansu, China.
Abstract:
Eg5, also known as KIF11, is a motor protein essential for establishing a bipolar spindle and ensuring proper chromosome congression during mitosis. It is amplified in various human cancers and serves as a critical oncogene driving tumour progression. However, the role and clinical significance of Eg5 in gastric cancer has remained elusive. In this study, we showed that Eg5 is upregulation in gastric cancer tissues and is negatively associated with patient prognosis. The ablation of Eg5 inhibits the proliferation and migration of gastric cancer cells and suppresses tumour growth in xenograft mice. Mechanistically, Eg5 ablation induces the formation of monopolar spindle, leading to cell apoptosis and consequent inhibition of tumour growth. Furthermore, Arry520 is demonstrated as a potent Eg5 inhibitor which blocks tumour growth by increasing the formation of cell monopolar spindle and inducing apoptosis. Arry520 exhibits efficiently therapeutic effects on gastric cancer in tumour organoid models, cell-derived xenografts and patient-derived xenografts (PDX) in mice. Collectively, our findings provide evidence for the oncogenic properties of the mitotic protein Eg5 and identify Arry520 as a promising strategy to combat gastric cancer.
Insights
Eg5 (KIF11), a motor protein, is upregulated in gastric cancer, driving tumor growth. Inhibiting Eg5 with Arry520 shows therapeutic potential by disrupting cell division and inducing apoptosis.
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Biology
Background:
- Eg5 (KIF11) is a crucial motor protein for mitosis, implicated as an oncogene in various cancers.
- The specific role of Eg5 in gastric cancer progression and its clinical significance were previously unclear.
Purpose of the Study:
- To investigate the role and clinical significance of Eg5 in gastric cancer.
- To evaluate the therapeutic potential of Eg5 inhibition in gastric cancer models.
Main Methods:
- Analysis of Eg5 expression in gastric cancer tissues.
- Functional studies involving Eg5 ablation in gastric cancer cells and xenograft models.
- Assessment of the Eg5 inhibitor Arry520 in vitro and in vivo, including organoid and PDX models.
Main Results:
- Eg5 is upregulated in gastric cancer and associated with poor patient prognosis.
- Eg5 ablation inhibits gastric cancer cell proliferation, migration, and tumor growth by inducing monopolar spindles and apoptosis.
- Arry520 effectively suppresses tumor growth by promoting monopolar spindle formation and apoptosis in various gastric cancer models.
Conclusions:
- Eg5 acts as an oncogene in gastric cancer, contributing to tumor progression.
- Arry520 is a promising therapeutic agent for gastric cancer, targeting Eg5-mediated mitotic defects.
More Related Videos
Related Concept Videos
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Gastric Motility
Peristaltic Waves and Chyme Formation
Upon food entry, the stomach initiates...

